{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T17:23:49Z","timestamp":1769880229001,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s10072-024-07896-9","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T03:27:38Z","timestamp":1733196458000},"page":"1807-1815","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nomogram for the prediction of relapse factors in patients with neuromyelitis optica spectrum disorder during rituximab treatment"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6918-8556","authenticated-orcid":false,"given":"Yanning","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9031-0472","authenticated-orcid":false,"given":"Dehui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,3]]},"reference":[{"key":"7896_CR1","doi-asserted-by":"publisher","first-page":"103465","DOI":"10.1016\/j.autrev.2023.103465","volume":"22","author":"P Siriratnam","year":"2023","unstructured":"Siriratnam P, Huda S, Butzkueven H et al (2023) A comprehensive review of the advances in neuromyelitis optica spectrum disorder.[J]. Autoimmun Rev 22:103465. https:\/\/doi.org\/10.1016\/j.autrev.2023.103465","journal-title":"Autoimmun Rev"},{"key":"7896_CR2","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/brain\/awz054","volume":"142","author":"J Palace","year":"2019","unstructured":"Palace J, Lin DY, Zeng D et al (2019) Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders.[J]. Brain 142:1310\u20131323. https:\/\/doi.org\/10.1093\/brain\/awz054","journal-title":"Brain"},{"key":"7896_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","volume":"6","author":"S Jarius","year":"2020","unstructured":"Jarius S, Paul F, Weinshenker BG et al (2020) Neuromyelitis optica.[J]. Nat Rev Dis Primers 6:85. https:\/\/doi.org\/10.1038\/s41572-020-0214-9","journal-title":"Nat Rev Dis Primers"},{"key":"7896_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/bpa.12099","volume":"24","author":"CF Lucchinetti","year":"2014","unstructured":"Lucchinetti CF, Guo Y, Popescu BF et al (2014) The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica.[J]. Brain Pathol 24:83\u201397. https:\/\/doi.org\/10.1111\/bpa.12099","journal-title":"Brain Pathol"},{"key":"7896_CR5","doi-asserted-by":"publisher","first-page":"102618","DOI":"10.1016\/j.conb.2022.102618","volume":"76","author":"DL Mora Cuervo","year":"2022","unstructured":"Mora Cuervo DL, Hansel G, Sato DK (2022) Immunobiology of neuromyelitis optica spectrum disorders.[J]. Curr Opin Neurobiol 76:102618. https:\/\/doi.org\/10.1016\/j.conb.2022.102618","journal-title":"Curr Opin Neurobiol"},{"key":"7896_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ncl.2020.09.003","volume":"39","author":"AI Wallach","year":"2021","unstructured":"Wallach AI, Tremblay M, Kister I (2021) Advances in the treatment of neuromyelitis optica spectrum disorder.[J]. Neurol Clin 39:35\u201349. https:\/\/doi.org\/10.1016\/j.ncl.2020.09.003","journal-title":"Neurol Clin"},{"key":"7896_CR7","doi-asserted-by":"publisher","first-page":"e140122193419","DOI":"10.2174\/1570163818666210519103001","volume":"19","author":"F Ali","year":"2022","unstructured":"Ali F, Sharma K, Anjum V et al (2022) Inebilizumab-cdon: USFDA approved for the treatment of NMOSD (neuromyelitis optica spectrum disorder).[J]. Curr Drug Discov Technol 19:e140122193419. https:\/\/doi.org\/10.2174\/1570163818666210519103001","journal-title":"Curr Drug Discov Technol"},{"key":"7896_CR8","doi-asserted-by":"publisher","first-page":"1166490","DOI":"10.3389\/fneur.2023.1166490","volume":"14","author":"S Aungsumart","year":"2023","unstructured":"Aungsumart S, Youngkong S, Dejthevaporn C et al (2023) Efficacy and safety of monoclonal antibody therapy in patients with neuromyelitis optica spectrum disorder: a systematic review and network meta-analysis.[J]. Front Neurol 14:1166490. https:\/\/doi.org\/10.3389\/fneur.2023.1166490","journal-title":"Front Neurol"},{"key":"7896_CR9","doi-asserted-by":"publisher","first-page":"732","DOI":"10.4103\/aian.AIAN_167_21","volume":"24","author":"VA Patil","year":"2021","unstructured":"Patil VA, Kamat SN, Lalkaka JA et al (2021) Efficacy and safety of rituximab in central nervous system demyelinating disorders.[J]. Ann Indian Acad Neurol 24:732\u2013739. https:\/\/doi.org\/10.4103\/aian.AIAN_167_21","journal-title":"Ann Indian Acad Neurol"},{"key":"7896_CR10","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/s1474-4422(20)30066-1","volume":"19","author":"M Tahara","year":"2020","unstructured":"Tahara M, Oeda T, Okada K et al (2020) Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.[J]. Lancet Neurol 19:298\u2013306. https:\/\/doi.org\/10.1016\/s1474-4422(20)30066-1","journal-title":"Lancet Neurol"},{"key":"7896_CR11","doi-asserted-by":"publisher","first-page":"101933","DOI":"10.1016\/j.msard.2020.101933","volume":"40","author":"Q Lu","year":"2020","unstructured":"Lu Q, Luo J, Hao H et al (2020) A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders.[J]. Mult Scler Relat Disord 40:101933. https:\/\/doi.org\/10.1016\/j.msard.2020.101933","journal-title":"Mult Scler Relat Disord"},{"key":"7896_CR12","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1212\/nxi.0000000000000061","volume":"2","author":"JS Perumal","year":"2015","unstructured":"Perumal JS, Kister I, Howard J et al (2015) Disease exacerbation after rituximab induction in neuromyelitis optica.[J]. Neurol Neuroimmunol Neuroinflamm 2:e61. https:\/\/doi.org\/10.1212\/nxi.0000000000000061","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"7896_CR13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.msard.2018.02.004","volume":"20","author":"E Maillart","year":"2018","unstructured":"Maillart E, Lippi A, Lubetzki C et al (2018) Early relapse after RTX initiation in a patient with NMO\/MS overlap syndrome: how long to conclude to a failure treatment?[J]. Mult Scler Relat Disord 20:220\u2013222. https:\/\/doi.org\/10.1016\/j.msard.2018.02.004","journal-title":"Mult Scler Relat Disord"},{"key":"7896_CR14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12883-019-1261-2","volume":"19","author":"F Gao","year":"2019","unstructured":"Gao F, Chai B, Gu C et al (2019) Effectiveness of rituximab in neuromyelitis optica: a meta-analysis.[J]. BMC Neurol 19:36. https:\/\/doi.org\/10.1186\/s12883-019-1261-2","journal-title":"BMC Neurol"},{"key":"7896_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/wnl.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.[J]. Neurology 85:177\u2013189. https:\/\/doi.org\/10.1212\/wnl.0000000000001729","journal-title":"Neurology"},{"key":"7896_CR16","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1001\/jamacardio.2023.2731","volume":"8","author":"I Iatan","year":"2023","unstructured":"Iatan I, Guan M, Humphries KH et al (2023) Atherosclerotic coronary plaque regression and risk of adverse cardiovascular events: a systematic review and updated meta-regression analysis.[J]. JAMA Cardiol 8:937\u2013945. https:\/\/doi.org\/10.1001\/jamacardio.2023.2731","journal-title":"JAMA Cardiol"},{"key":"7896_CR17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/fampra\/cmw031","volume":"33","author":"VY Guo","year":"2016","unstructured":"Guo VY, Yu EY, Wong C et al (2016) Validation of a nomogram for predicting regression from impaired fasting glucose to normoglycaemia to facilitate clinical decision making.[J]. Fam Pract 33:401\u2013407. https:\/\/doi.org\/10.1093\/fampra\/cmw031","journal-title":"Fam Pract"},{"key":"7896_CR18","doi-asserted-by":"publisher","first-page":"e0008467","DOI":"10.1371\/journal.pntd.0008467","volume":"14","author":"L de Moraes","year":"2020","unstructured":"de Moraes L, Cerqueira-Silva T, Nobrega V et al (2020) A clinical scoring system to predict long-term arthralgia in Chikungunya disease: a cohort study.[J]. PLoS Negl Trop Dis 14:e0008467. https:\/\/doi.org\/10.1371\/journal.pntd.0008467","journal-title":"PLoS Negl Trop Dis"},{"key":"7896_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v033.i01","volume":"33","author":"J Friedman","year":"2010","unstructured":"Friedman J, Hastie T, Tibshirani R (2010) Regularization paths for generalized linear models via coordinate descent.[J]. J Stat Softw 33:1\u201322","journal-title":"J Stat Softw"},{"key":"7896_CR20","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1467-9868.2011.01004.x","volume":"74","author":"R Tibshirani","year":"2012","unstructured":"Tibshirani R, Bien J, Friedman J et al (2012) Strong rules for discarding predictors in lasso-type problems.[J]. J R Stat Soc Ser B Stat Methodol 74:245\u2013266. https:\/\/doi.org\/10.1111\/j.1467-9868.2011.01004.x","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"key":"7896_CR21","unstructured":"Jr FEH. Regression Modeling Strategies (Documentation for package \u2018rms\u2019 version 6.7-1), https:\/\/hbiostat.org\/R\/rms\/ (2023)"},{"key":"7896_CR22","unstructured":"Xavier R (2023) Display and analyze ROC curves (Documentation for package \u2018pROC\u2019 version 1.18.4).[J]"},{"key":"7896_CR23","unstructured":"Lele S (2023) Resource selection (probability) functions for use-availability (documentation for package \u2018resourceselection\u2019 version 0.3-6), https:\/\/CRAN.R-project.org\/package=ResourceSelection"},{"key":"7896_CR24","unstructured":"Brown M (2018) Risk model decision analysis (documentation for package \u2018rmda\u2019 version 1.6.), http:\/\/mdbrown.github.io\/rmda\/"},{"key":"7896_CR25","doi-asserted-by":"publisher","first-page":"578285","DOI":"10.1016\/j.jneuroim.2024.578285","volume":"387","author":"C Zhang","year":"2024","unstructured":"Zhang C, Liu R, Gao B et al (2024) Efficacy and safety of low- and ultralow-dose rituximab in neuromyelitis optica spectrum disorder.[J]. J Neuroimmunol 387:578285. https:\/\/doi.org\/10.1016\/j.jneuroim.2024.578285","journal-title":"J Neuroimmunol"},{"key":"7896_CR26","doi-asserted-by":"publisher","first-page":"642","DOI":"10.3389\/fneur.2020.00642","volume":"11","author":"H Xiao","year":"2020","unstructured":"Xiao H, Zeng W, Li L et al (2020) Retrospective observation of low-dose rituximab treatment in Chinese patients with neuromyelitis optica spectrum disorders in a real-world setting.[J]. Front Neurol 11:642. https:\/\/doi.org\/10.3389\/fneur.2020.00642","journal-title":"Front Neurol"},{"key":"7896_CR27","doi-asserted-by":"publisher","first-page":"117204","DOI":"10.1016\/j.jns.2020.117204","volume":"419","author":"A Casallas-Vanegas","year":"2020","unstructured":"Casallas-Vanegas A, Gomez-Figueroa E, de Sar\u00e1chaga AJ et al (2020) Rituximab efficacy at different initial and maintenance doses in neuromyelitis optica spectrum disorder: experience from a national health institute in M\u00e9xico.[J]. J Neurol Sci 419:117204. https:\/\/doi.org\/10.1016\/j.jns.2020.117204","journal-title":"J Neurol Sci"},{"key":"7896_CR28","doi-asserted-by":"publisher","first-page":"e064216","DOI":"10.1136\/bmjopen-2022-064216","volume":"12","author":"J Liu","year":"2022","unstructured":"Liu J, Shen Q, Xie L et al (2022) Protocol for an open-label, single-arm, multicentre clinical study to evaluate the efficacy and safety of rituximab in the first episode of paediatric idiopathic nephrotic syndrome.[J]. BMJ Open 12:e064216. https:\/\/doi.org\/10.1136\/bmjopen-2022-064216","journal-title":"BMJ Open"},{"key":"7896_CR29","doi-asserted-by":"publisher","first-page":"637932","DOI":"10.3389\/fneur.2021.637932","volume":"12","author":"S Zhao","year":"2021","unstructured":"Zhao S, Zhou H, Xu Q et al (2021) Efficacy of low-dose rituximab on neuromyelitis optica-associated optic neuritis.[J]. Front Neurol 12:637932. https:\/\/doi.org\/10.3389\/fneur.2021.637932","journal-title":"Front Neurol"},{"key":"7896_CR30","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1007\/s00415-022-11048-4","volume":"269","author":"Y Du","year":"2022","unstructured":"Du Y, Li C, Hao YF et al (2022) Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis.[J]. J Neurol 269:4229\u20134240. https:\/\/doi.org\/10.1007\/s00415-022-11048-4","journal-title":"J Neurol"},{"key":"7896_CR31","doi-asserted-by":"publisher","first-page":"e2504","DOI":"10.1212\/wnl.0000000000201260","volume":"99","author":"P Barreras","year":"2022","unstructured":"Barreras P, Vasileiou ES, Filippatou AG et al (2022) Long-term effectiveness and safety of rituximab in neuromyelitis optica spectrum disorder and MOG antibody disease.[J]. Neurology 99:e2504\u2013e2516. https:\/\/doi.org\/10.1212\/wnl.0000000000201260","journal-title":"Neurology"},{"key":"7896_CR32","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1007\/s10072-021-05609-0","volume":"43","author":"L Zhang","year":"2022","unstructured":"Zhang L, Tian J, Dong X et al (2022) Efficacy of azathioprine, mycophenolate mofetil, and rituximab in the treatment of neuromyelitis optica spectrum disorder and analysis of prognostic factors.[J]. Neurol Sci 43:2651\u20132658. https:\/\/doi.org\/10.1007\/s10072-021-05609-0","journal-title":"Neurol Sci"},{"key":"7896_CR33","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","volume":"264","author":"Z Nikoo","year":"2017","unstructured":"Nikoo Z, Badihian S, Shaygannejad V et al (2017) Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial.[J]. J Neurol 264:2003\u20132009. https:\/\/doi.org\/10.1007\/s00415-017-8590-0","journal-title":"J Neurol"},{"key":"7896_CR34","doi-asserted-by":"publisher","first-page":"104127","DOI":"10.1016\/j.msard.2022.104127","volume":"68","author":"K Wei","year":"2022","unstructured":"Wei K, Nie Q, Zhu Y et al (2022) Different doses of rituximab for the therapy of neuromyelitis optica spectrum disorder: a systematic review and meta-analysis.[J]. Mult Scler Relat Disord 68:104127. https:\/\/doi.org\/10.1016\/j.msard.2022.104127","journal-title":"Mult Scler Relat Disord"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07896-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-024-07896-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07896-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T17:55:32Z","timestamp":1742320532000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-024-07896-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,3]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["7896"],"URL":"https:\/\/doi.org\/10.1007\/s10072-024-07896-9","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,3]]},"assertion":[{"value":"22 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the medical ethics committees of the PLA General Hospital. This research posed minimal risks to participants, and their privacy and personal information were effectively safeguarded throughout the study. Consequently, obtaining informed consent was deemed unnecessary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare that there are no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}